Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Avidity posts positive Phase 1/2 topline data in myotonic dystrophy 1

Avidity Biosciences (NASDAQ:RNA) reported positive topline data from the Phase 1/2 MARINA clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal...

April 28, 2023

Markets

Cantor starts Disc Medicine at OW; PT $45

Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...

April 28, 2023

Markets

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given updated data released in the fourth...

April 27, 2023

Developments

SAB posts positive Phase 3 results in high-risk COVID-19 patients

SAB Biotherapeutics (NASDAQ:SABS) reported positive top-line results from the Phase 3 National Institutes of Health’s ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at...

April 26, 2023

Developments

Morphic posts positive cohort data in ulcerative colitis

Morphic Therapeutic (NASDAQ:MORF) reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with...

April 25, 2023

Developments

Lyra restarts Phase 3 trial in chronic rhinosinusitis

Lyra Therapeutics (NASDAQ:LYRA) resumed screening and enrollment in ENLIGHTEN II, its second Phase 3 clinical trial of LYR-210 in patients with chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant...

April 25, 2023

Developments

Blue Water Vaccines changes name to Blue Water Biotech

Blue Water Vaccines changed its corporate name to Blue Water Biotech, following its recent acquisition of ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia, which has begun Blue Water’s transition into...

April 25, 2023

Developments

Lantheus, POINT get FDA fast track for mCRPC

The FDA granted Lantheus Holdings (NASDAQ:LNTH) and POINT Biopharma (NASDAQ:PNT) fast track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC). PNT2002 is an...

April 24, 2023

Executive Moves

Jeffrey Dayno named president, CEO of Harmony Biosciences

Harmony Biosciences (NASDAQ:HRMY) appointed Jeffrey Dayno, M.D., as president and CEO, and a member of the board. Dr. Dayno, a nationally recognized neuroscience expert, joined Harmony as CMO and EVP when the company...

April 24, 2023

Markets

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

Stifel upgraded IDEADYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” and raised its price target to $24 from $18 following additional darovasertib data in uveal melanoma, which revealed an improved mPFS in first-line...

April 24, 2023

Markets

Stifel starts Disc Medicine at buy; PT $37

Stifel launched coverage of Disc Medicine (NASDAQ:IRON) with a “buy” rating and $37 price target. The stock closed at $28.10, up $2.34, on April 20. “Our positive thesis is predicated on optimism for the company’s lead...

April 21, 2023

Developments

Visus posts positive Phase 3 data to treat presbyopia

Visus Therapeutics reported positive topline results from its Phase 3 pivotal BRIO-I trial, demonstrating highly statistically significant improvements in near and distance binocular visual acuity at multiple...

April 20, 2023

Avidity posts positive Phase 1/2 topline data in myotonic dystrophy 1

Cantor starts Disc Medicine at OW; PT $45

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

SAB posts positive Phase 3 results in high-risk COVID-19 patients

Morphic posts positive cohort data in ulcerative colitis

Lyra restarts Phase 3 trial in chronic rhinosinusitis

Blue Water Vaccines changes name to Blue Water Biotech

Lantheus, POINT get FDA fast track for mCRPC

Jeffrey Dayno named president, CEO of Harmony Biosciences

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

Stifel starts Disc Medicine at buy; PT $37

Visus posts positive Phase 3 data to treat presbyopia

General

More